IMV's pipeline reflects our focus on Immuno-Oncology and other serious diseases. Our lead candidate, DPX-Survivac is being evaluated in three ongoing Phase 2 studies as a single regimen or in combination with Merck's Keytruda.
View our recent investor presentations, which highlight the progress of our clinical programs and key upcoming milestones.
Collaborations at the frontier of R&D in cancer and serious diseases are a vital component of our program. We have a strong track record of successful, long-term partnerships focused on building value and expanding treatment options.
Clinical-stage biopharmaceutical company leveraging our proprietary drug delivery platform, DPX, to generate cancer-targeted T cells. Our lead candidate, DPX-Survivac, is a first of a novel class of immunotherapy and targets survivin, an antigen present in more than 20 solid and hematological tumor types. DPX-Survivac is being evaluated in three ongoing Phase 2 studies: (1) as a single regimen in advanced ovarian cancer, and in a combination regimen with Keytruda in (2) r/r DLBCL and (3) multiple solid tumors. Data to date have exhibited a favorable safety profile and encouraging signs of anti-tumor activity, including T cell responses that correlate with treatment and durable PFS; readouts from all three studies anticipated between 4Q19 and 1H20.
The method and manner in which directives are delivered to our immune systems, and their initial responses, are critical components of leveraging the disease-fighting potential of human immunity. At IMV, we believe that we have found a groundbreaking way to deliver the messages to command and sustain that pivotal response. By using our unique delivery platform, we believe we have the capacity to mobilize our immune system in a manner that will open a new era in immunotherapies and disease prevention.
Driven by the fundamental science underscoring our platform, our R&D teams leverage the unique mechanism of action of our 100% oil-based delivery formulations, coupled with proprietary targets, to harness human immunity in a truly novel way.
Our lead candidate is priming tumors for today’s strongest anti-cancer agents. We are focused on developing combination therapies that can improve treatment outcomes for some of today’s toughest cancers. Read about our clinical trials here.
Disrupting Disease. Transforming the Power of Human Immunity. We are committed to building value for our partners and our investors, while working to help fill the significant gaps in today’s treatment landscape.
Working at IMV brings you to the forefront of cutting-edge science and research for cancer and other serious diseases. We’ve worked hard to build a culture of innovation and collaboration.Learn more about life at IMV